Diabetes care company Eli Lilly and Company (NYSE:LLY) reported on Friday the receipt of approval from US Food and Drug Administration (FDA) for Trulicity for the reduction of major adverse cardiovascular events (MACE) in adults with type 2 diabetes.

Trulicity (dulaglutide) is the first and only type 2 diabetes medicine approved to reduce the risk of MACE for both primary and secondary prevention type 2 diabetes patients who have established cardiovascular (CV) disease or multiple cardiovascular risk factors.

Additionally, Trulicity 1.5 mg, a weekly glucagon-like peptide 1 receptor agonist (GLP-1 RA), compared to placebo, is both added to standard of care (according to local standard of care guidelines), on cardiovascular (CV) events in adults with type 2 diabetes, added the company.

REWIND, the company's cardiovascular multicenter, randomized, double-blind, placebo-controlled outcomes trial of Trulicity (dulaglutide) in 1.5 mg, showed a significant risk reduction in MACE, a composite endpoint of nonfatal myocardial infarction (heart attack), nonfatal stroke or CV death, disclosed the company.

Since 2014, Trulicity has been available in the US and is the number one prescribed GLP-1 RA. In addition to its proven glycemic efficacy and easy-to-use device, it can now be prescribed to help people with type 2 diabetes reduce their risk of CV events, concluded the company.